These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37768283)

  • 1. Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Oh SJ; Kim HJ; Lee CK
    Aliment Pharmacol Ther; 2023 Oct; 58(8):840-841. PubMed ID: 37768283
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
    Andrew B; Zhou A; Trinh S; Srinivasan A; Vasudevan A
    Aliment Pharmacol Ther; 2023 Oct; 58(8):838-839. PubMed ID: 37768293
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
    Faye AS; Jess T
    Gut; 2024 Apr; 73(5):871-872. PubMed ID: 37226847
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibiotics and inflammatory bowel diseases.
    Scribano ML; Prantera C
    Dig Dis; 2013; 31(3-4):379-84. PubMed ID: 24246992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
    Oh SJ; Kim HJ; Lee CK
    Aliment Pharmacol Ther; 2023 Jul; 58(2):256-257. PubMed ID: 37352158
    [No Abstract]   [Full Text] [Related]  

  • 6. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripartum Antibiotics Promote Gut Dysbiosis, Loss of Immune Tolerance, and Inflammatory Bowel Disease in Genetically Prone Offspring.
    Miyoshi J; Bobe AM; Miyoshi S; Huang Y; Hubert N; Delmont TO; Eren AM; Leone V; Chang EB
    Cell Rep; 2017 Jul; 20(2):491-504. PubMed ID: 28700948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.
    Schulberg J; De Cruz P
    Intern Med J; 2016 Mar; 46(3):266-73. PubMed ID: 26968595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.
    Lee JY; Cevallos SA; Byndloss MX; Tiffany CR; Olsan EE; Butler BP; Young BM; Rogers AWL; Nguyen H; Kim K; Choi SW; Bae E; Lee JH; Min UG; Lee DC; Bäumler AJ
    Cell Host Microbe; 2020 Aug; 28(2):273-284.e6. PubMed ID: 32668218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter: dermatological complications with therapy for inflammatory bowel disease--authors' reply.
    Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2014 Jan; 39(2):233-4. PubMed ID: 24330245
    [No Abstract]   [Full Text] [Related]  

  • 11. Intestinal dysbiosis in inflammatory bowel disease.
    Kaur N; Chen CC; Luther J; Kao JY
    Gut Microbes; 2011; 2(4):211-6. PubMed ID: 21983063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Mahmoud R; Schultheiss JPD; Fidder HH; Oldenburg B
    Aliment Pharmacol Ther; 2022 Feb; 55(4):499-500. PubMed ID: 35092052
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 Jul; 56(1):179. PubMed ID: 35689310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Microbiome and Antibiotics in Autoimmune Diseases.
    Vangoitsenhoven R; Cresci GAM
    Nutr Clin Pract; 2020 Jun; 35(3):406-416. PubMed ID: 32319703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1134. PubMed ID: 26427756
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.
    Ewaschuk JB; Tejpar QZ; Soo I; Madsen K; Fedorak RN
    Curr Gastroenterol Rep; 2006 Dec; 8(6):486-98. PubMed ID: 17105688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibiotics for inflammatory bowel disease].
    Fujii H; Koyama F; Nakajima Y
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():343-7. PubMed ID: 23126115
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Aug; 54(4):538-539. PubMed ID: 34331805
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Aug; 60(3):427-428. PubMed ID: 38922940
    [No Abstract]   [Full Text] [Related]  

  • 20. "Role of exercise in preventing and restoring gut dysbiosis in patients with inflammatory bowel disease": A letter to the editor.
    Mc Gettigan N; O'Toole A; Boland K
    World J Gastroenterol; 2022 Feb; 28(8):878-880. PubMed ID: 35317102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.